A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D

PHASE3CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

May 9, 2023

Primary Completion Date

October 29, 2024

Study Completion Date

December 3, 2024

Conditions
HypoglycemiaType 1 Diabetes
Interventions
DRUG

Dasiglucagon

Dasiglucagon, 0.6 mg/0.6 mL or 0.3 mg/0.3 mL will be administered as an under the skin (subcutaneous, s.c.) injection by a prefilled syringe, into the buttocks.

Trial Locations (2)

30329

Children's Healthcare of Atlanta, Atlanta

76104

Cook Childrens Health Care System, Fort Worth

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Novo Nordisk A/S

INDUSTRY

lead

Zealand Pharma

INDUSTRY

NCT05378672 - A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D | Biotech Hunter | Biotech Hunter